29 related articles for article (PubMed ID: 22497435)
1. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time.
Bjornsdottir HH; Rawshani A; Rawshani A; Franzén S; Svensson AM; Sattar N; Gudbjörnsdottir S
Sci Rep; 2020 Oct; 10(1):17376. PubMed ID: 33060631
[TBL] [Abstract][Full Text] [Related]
2. Does long-term use of antidiabetic drugs changes cancer risk?
Liu YC; Nguyen PA; Humayun A; Chien SC; Yang HC; Asdary RN; Syed-Abdul S; Hsu MH; Moldovan M; Yen Y; Li YJ; Jian WS; Iqbal U
Medicine (Baltimore); 2019 Oct; 98(40):e17461. PubMed ID: 31577776
[TBL] [Abstract][Full Text] [Related]
3. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.
Gallagher EJ; LeRoith D
Physiol Rev; 2015 Jul; 95(3):727-48. PubMed ID: 26084689
[TBL] [Abstract][Full Text] [Related]
4. The association between type 2 diabetes mellitus and women cancer: the epidemiological evidences and putative mechanisms.
Joung KH; Jeong JW; Ku BJ
Biomed Res Int; 2015; 2015():920618. PubMed ID: 25866823
[TBL] [Abstract][Full Text] [Related]
5. Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes.
Joseph JJ; Donner TW
Vasc Health Risk Manag; 2015; 11():107-16. PubMed ID: 25657589
[TBL] [Abstract][Full Text] [Related]
6. Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies.
Karlstad O; Starup-Linde J; Vestergaard P; Hjellvik V; Bazelier MT; Schmidt MK; Andersen M; Auvinen A; Haukka J; Furu K; de Vries F; De Bruin ML
Curr Drug Saf; 2013 Nov; 8(5):333-48. PubMed ID: 24215311
[TBL] [Abstract][Full Text] [Related]
7. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
[TBL] [Abstract][Full Text] [Related]
8. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
[TBL] [Abstract][Full Text] [Related]
9. The links between insulin resistance, diabetes, and cancer.
Orgel E; Mittelman SD
Curr Diab Rep; 2013 Apr; 13(2):213-22. PubMed ID: 23271574
[TBL] [Abstract][Full Text] [Related]
10. Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies.
Wu JW; Filion KB; Azoulay L; Doll MK; Suissa S
Diabetes Care; 2016 Mar; 39(3):486-94. PubMed ID: 26740633
[TBL] [Abstract][Full Text] [Related]
11. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
12. Insulin glargine use and short-term incidence of breast cancer - a four-year population-based observation.
Ljung R; Talbäck M; Haglund B; Jonasson JM; Gudbjörnsdòttir S; Steineck G
Acta Oncol; 2012 Mar; 51(3):400-2. PubMed ID: 22497435
[No Abstract] [Full Text] [Related]
13. The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes.
Lind M; Fahlén M; Eliasson B; Odén A
Prim Care Diabetes; 2012 Apr; 6(1):53-9. PubMed ID: 22056422
[TBL] [Abstract][Full Text] [Related]
14. Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin.
Juhaeri J; Gao S; Dai WS
Pharmacoepidemiol Drug Saf; 2009 Jun; 18(6):497-503. PubMed ID: 19326365
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
